Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Revivicor Inc. maintains a company patent portfolio that currently includes 1 pending office action. This action is being reviewed by 1 distinct examiner, indicating a focused interaction with the patent office. The data shows 0 distinct art units for this portfolio, which may suggest that the pending matter is in a unique or transitional classification. This singular focus means that the company's current prosecution activity is limited to this one specific engagement, without the complexity of multiple technical departments.
The busiest examiner for this portfolio is PARKIN, JEFFREY S, who is responsible for 1 pending office action. Because the total number of pending office actions is 1, this examiner manages the entirety of the company's active workload. Practitioners should note that the prosecution strategy is currently centralized under this single point of contact. This centralization places significant importance on the examiner's individual interpretation of the claims, as there are no other pending matters to provide a baseline for comparison.
The involvement of 1 distinct examiner for the only pending matter removes the need for coordinating between different prosecution styles. The workload is distributed such that the busiest examiner handles the 1 pending office action, representing the full scope of the company's current interactions with the patent office. This streamlined structure allows for a direct and consistent dialogue regarding the pending intellectual property. The absence of multiple art units further simplifies the current management of the portfolio, focusing all efforts on the single active case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634524 | NOVEL SEROLOGY ASSAY FOR THE DETECTION OF PORCINE VIRUSES | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634524 | NOVEL SEROLOGY ASSAY FOR THE DETECTION OF PORCINE VIRUSES | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRevivicor Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Allen has the most, with 1 of Revivicor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.